atracurium Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
neuromuscular blocking agents with rigid structure	259	64228-79-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: atracurium tracrium atracurium besylate	A non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents. Molecular weight: 929.16 Formula: C53H72N2O12 CLOGP: 3.50 LIPINSKI: 2 HAC: 14 HDO: 0 TPSA: 126.44 ALOGS: -7.63 ROTB: 26 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

atracurium
tracrium
atracurium besylate

A non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents.

Molecular weight: 929.16
Formula: C53H72N2O12
CLOGP: 3.50
LIPINSKI: 2
HAC: 14
HDO: 0
TPSA: 126.44
ALOGS: -7.63
ROTB: 26

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	0	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	8.50 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.65 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	0.10 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	5.70 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.52 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	0.31 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Nov. 23, 1983	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anaphylactic shock	569.72	43.29	147	2529	20127	46663259
Anaphylactic reaction	236.50	43.29	95	2581	53017	46630369
Bronchospasm	176.77	43.29	56	2620	15651	46667735
Hypotension	175.06	43.29	127	2549	232462	46450924
Oliguria	89.29	43.29	29	2647	8730	46674656
Tachycardia	78.04	43.29	56	2620	99566	46583820
Cardiac arrest	73.51	43.29	52	2624	90347	46593039
Pulseless electrical activity	66.07	43.29	22	2654	7145	46676241
Circulatory collapse	57.56	43.29	27	2649	21597	46661789
Shock	57.29	43.29	27	2649	21818	46661568
Patent ductus arteriosus	57.07	43.29	17	2659	3845	46679541
Infantile apnoea	55.24	43.29	12	2664	764	46682622
Stress cardiomyopathy	52.79	43.29	19	2657	7765	46675621
Foetal exposure during pregnancy	51.33	43.29	28	2648	30719	46652667
Wrong product administered	50.77	43.29	17	2659	5613	46677773
Ventricular fibrillation	48.99	43.29	20	2656	11476	46671910
Post procedural complication	46.09	43.29	21	2655	15708	46667678
Acute respiratory distress syndrome	45.21	43.29	23	2653	21899	46661487
Foetal growth restriction	44.42	43.29	16	2660	6551	46676835
Tonsillar hypertrophy	43.62	43.29	10	2666	814	46682572

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anaphylactic shock	355.29	39.06	97	1930	13896	29936555
Bronchospasm	190.89	39.06	56	1971	10282	29940169
Anaphylactic reaction	189.40	39.06	71	1956	27911	29922540
Hypotension	74.80	39.06	79	1948	200486	29749965
Circulatory collapse	61.12	39.06	29	1998	20185	29930266
Oxygen saturation decreased	54.89	39.06	35	1992	43405	29907046
Trigemino-cardiac reflex	54.12	39.06	9	2018	111	29950340
Tachycardia	42.37	39.06	37	1990	73702	29876749
Erythema	40.80	39.06	37	1990	77414	29873037
Bradycardia	39.91	39.06	34	1993	65492	29884959
Procedural hypotension	39.80	39.06	10	2017	1015	29949436
Airway complication of anaesthesia	39.46	39.06	7	2020	129	29950322

Pharmacologic Action:

Source	Code	Description
ATC	M03AC04	MUSCULO-SKELETAL SYSTEM MUSCLE RELAXANTS MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS Other quaternary ammonium compounds
FDA EPC	N0000175720	Nondepolarizing Neuromuscular Blocker
FDA PE	N0000175732	Neuromuscular Nondepolarizing Blockade
CHEBI has role	CHEBI:48878	agents antinicotiniques
CHEBI has role	CHEBI:51371	muscle relaxants
MeSH PA	D018678	Cholinergic Agents
MeSH PA	D018680	Cholinergic Antagonists
MeSH PA	D009465	Neuromuscular Agents
MeSH PA	D009466	Neuromuscular Blocking Agents
MeSH PA	D003473	Neuromuscular Nondepolarizing Agents
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018733	Nicotinic Antagonists
MeSH PA	D018373	Peripheral Nervous System Agents

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Muscle relaxation, function	indication	11977004
General anesthesia	indication	50697003
Skeletal Muscle Relaxation for Endotracheal Intubation	indication
Hypocalcemia	contraindication	5291005
Disorder of lung	contraindication	19829001	DOID:850
Hypokalemia	contraindication	43339004
Low blood pressure	contraindication	45007003
Eaton-Lambert syndrome	contraindication	56989000	DOID:0050214
Hypermagnesemia	contraindication	66978005
Myasthenia gravis	contraindication	91637004	DOID:437
Disorder of electrolytes	contraindication	237840007
Hypothermia	contraindication	386689009
Malignant hyperthermia	contraindication	405501007

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Acetylcholine receptor	Ion channel	P02708 P11230 Q07001	ACHA_HUMAN ACHB_HUMAN ACHD_HUMAN	ANTAGONIST	IC50	7.77	WOMBAT-PK	CHEMBL
Neuronal acetylcholine receptor subunit alpha-2	Ion channel	Q15822	ACHA2_HUMAN				WOMBAT-PK
Small conductance calcium-activated potassium channel protein 3	Ion channel		KCNN3_RAT		Ki	5.23	CHEMBL

External reference:

ID	Source
2GQ1IRY63P	UNII
4019619	VUID
N0000147713	NUI
D00758	KEGG_DRUG
64228-81-5	SECONDARY_CAS_RN
4018778	VANDF
4019619	VANDF
C0004234	UMLSCUI
CHEBI:2914	CHEBI
CHEMBL1360	ChEMBL_ID
CHEMBL1200527	ChEMBL_ID
DB13295	DRUGBANK_ID
DB00732	DRUGBANK_ID
D001279	MESH_DESCRIPTOR_UI
47319	PUBCHEM_CID
4734	INN_ID
9537	IUPHAR_LIGAND_ID
1218	RXNORM
1341	MMSL
397	MMSL
4228	MMSL
d00173	MMSL
002409	NDDF
013420	NDDF
372835000	SNOMEDCT_US
72752006	SNOMEDCT_US
74074008	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Atracurium Besylate	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1105	INJECTION, SOLUTION	10 mg	INTRAVENOUS	ANDA	12 sections
Atracurium Besylate	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1109	INJECTION, SOLUTION	10 mg	INTRAVENOUS	ANDA	12 sections
Atracurium Besylate	HUMAN PRESCRIPTION DRUG LABEL	1	25021-659	INJECTION, SOLUTION	10 mg	INTRAVENOUS	ANDA	22 sections
Atracurium Besylate	HUMAN PRESCRIPTION DRUG LABEL	1	25021-659	INJECTION, SOLUTION	10 mg	INTRAVENOUS	ANDA	22 sections
Atracurium Besylate	HUMAN PRESCRIPTION DRUG LABEL	1	25021-672	INJECTION, SOLUTION	10 mg	INTRAVENOUS	ANDA	22 sections
Atracurium Besylate	HUMAN PRESCRIPTION DRUG LABEL	1	25021-672	INJECTION, SOLUTION	10 mg	INTRAVENOUS	ANDA	22 sections
Atracurium Besylate	Human Prescription Drug Label	1	55150-216	INJECTION, SOLUTION	50 mg	INTRAVENOUS	ANDA	20 sections
Atracurium Besylate	Human Prescription Drug Label	1	55150-217	INJECTION, SOLUTION	100 mg	INTRAVENOUS	ANDA	20 sections
Atracurium Besylate	HUMAN PRESCRIPTION DRUG LABEL	1	71288-701	INJECTION, SOLUTION	10 mg	INTRAVENOUS	ANDA	23 sections
Atracurium Besylate	HUMAN PRESCRIPTION DRUG LABEL	1	71288-702	INJECTION, SOLUTION	10 mg	INTRAVENOUS	ANDA	23 sections